# Xtant Medical Holdings, Inc.: Form 10-Q/A for the period ended Jun 30, 2017

- Company: [Xtant Medical Holdings, Inc.](/companies/xtnt.md) (CIK 1453593)
- Form: 10-Q/A
- Filed: 2018-03-30
- Accepted by EDGAR: Mar 30, 2018, 17:26 ET
- Period: 2017-06-30
- Accession: 0001144204-18-018329
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1453593/000114420418018329/tv481831_10qa.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1453593/000114420418018329/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2017-04-01 to 2017-06-30 | $7.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2017-01-01 to 2017-06-30 | $15.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2017-04-01 to 2017-06-30 | $13.5m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2017-01-01 to 2017-06-30 | $28.4m | us-gaap:GrossProfit |
| Research and development | 3 months, 2017-04-01 to 2017-06-30 | $640.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2017-01-01 to 2017-06-30 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2017-04-01 to 2017-06-30 | −$4.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2017-01-01 to 2017-06-30 | −$7.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-04-01 to 2017-06-30 | $3.3m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2017-01-01 to 2017-06-30 | $6.7m | us-gaap:InterestExpense |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | −$9.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-01-01 to 2017-06-30 | −$15.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | −$0.54 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2017-01-01 to 2017-06-30 | −$0.85 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-04-01 to 2017-06-30 | −$0.54 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2017-01-01 to 2017-06-30 | −$0.85 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-04-01 to 2017-06-30 | 18,092,603 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2017-01-01 to 2017-06-30 | 18,012,959 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2017-01-01 to 2017-06-30 | −$756.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2017-01-01 to 2017-06-30 | $1.1m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | at 2017-06-30 | $1.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-06-30 | $43.3m | us-gaap:AssetsCurrent |
| Total assets | at 2017-06-30 | $133.7m | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $20.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-06-30 | $155.6m | us-gaap:Liabilities |
| Long-term debt | at 2017-06-30 | $134.0m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2017-06-30 | −$21.9m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1453593/000114420418018329/tv481831_10qa.htm

Filed Mar 30, 2018.
Source: SEC EDGAR, the filing index for accession 0001144204-18-018329. Last ingested by Listed: Oct 24, 2026, 15:08 ET. No prices; not investment advice.
